Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshihiro Shibata

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Anti-Cancer Drugs|June 9, 2016
Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patientsTsuyoshi Shirakawa, Michitaka Nakano, Kenta Nio, et al.
Anticancer Research|April 13, 2016
Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal CancerShuji Arita, Tsuyoshi Shirakawa, Yuzo Matsushita, et al.
ACS Medicinal Chemistry Letters|May 18, 2019
Discovery of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors with Antitumor ActivityToru Taniguchi, Hiroaki Inagaki, Daichi Baba, et al.
Molecular Cancer Therapeutics|January 9, 2023
Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated MelanomaKohei Takano, Yoichi Munehira, Mana Hatanaka, et al.
Bioorganic & Medicinal Chemistry|April 15, 2004
Potent and orally active ET(A) selective antagonists with 5,7-diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acid structuresTakashi Yoshizumi, Hirobumi Takahashi, Norikazu Ohtake, et al.
Cancer Chemotherapy and Pharmacology|July 26, 2018
The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancerKyoko Yamaguchi, Hitoshi Kusaba, Akitaka Makiyama, et al.
Cancer Chemotherapy and Pharmacology|June 28, 2017
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancerKotoe Takayoshi, Hitoshi Kusaba, Masato Uenomachi, et al.
Anticancer Research|January 1, 2015
Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in JapanGen Hirano, Akitaka Makiyama, Chinatsu Makiyama, et al.
ACS Medicinal Chemistry Letters|April 20, 2023
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical UseSatoru Ito, Sachie Otsuki, Hirokazu Ohsawa, et al.
British Journal of Cancer|March 24, 2020
OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibodyHirofumi Ohmura, Kyoko Yamaguchi, Fumiyasu Hanamura, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Anti-Cancer Drugs|June 9, 2016
Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patientsTsuyoshi Shirakawa, Michitaka Nakano, Kenta Nio, et al.
Anticancer Research|April 13, 2016
Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal CancerShuji Arita, Tsuyoshi Shirakawa, Yuzo Matsushita, et al.
ACS Medicinal Chemistry Letters|May 18, 2019
Discovery of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors with Antitumor ActivityToru Taniguchi, Hiroaki Inagaki, Daichi Baba, et al.
Molecular Cancer Therapeutics|January 9, 2023
Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated MelanomaKohei Takano, Yoichi Munehira, Mana Hatanaka, et al.
Bioorganic & Medicinal Chemistry|April 15, 2004
Potent and orally active ET(A) selective antagonists with 5,7-diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acid structuresTakashi Yoshizumi, Hirobumi Takahashi, Norikazu Ohtake, et al.
Cancer Chemotherapy and Pharmacology|July 26, 2018
The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancerKyoko Yamaguchi, Hitoshi Kusaba, Akitaka Makiyama, et al.
Cancer Chemotherapy and Pharmacology|June 28, 2017
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancerKotoe Takayoshi, Hitoshi Kusaba, Masato Uenomachi, et al.
Anticancer Research|January 1, 2015
Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in JapanGen Hirano, Akitaka Makiyama, Chinatsu Makiyama, et al.
ACS Medicinal Chemistry Letters|April 20, 2023
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical UseSatoru Ito, Sachie Otsuki, Hirokazu Ohsawa, et al.
British Journal of Cancer|March 24, 2020
OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibodyHirofumi Ohmura, Kyoko Yamaguchi, Fumiyasu Hanamura, et al.
Pageof 6